^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/25/2024
Excerpt:
HR-Negative and HER2-Negative (Triple-Negative Breast Cancer...Germline BRCA1/2 mutation...PARPi (olaparib, talazoparib) (Category 1, preferred)
Source:
Published date:
12/10/2021
Excerpt:
Recommendation 1.4...Patients with metastatic triple-negative breast cancer with germline BRCA1 or 2 mutations who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic disease setting may be offered an oral poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib or talazoparib) rather than chemotherapy...
DOI:
10.1200/JCO.21.01374
Source:
Title:
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Published date:
07/19/2018
Excerpt:
A PARPi (olaparib or talazaparib) is a reasonable treatment option for patients with BRCA-associated advanced TNBC or luminal (after progression on ET)...
DOI:
10.1093/annonc/mdy192
Title:
Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Excerpt:
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
Source:
Title:
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
Excerpt:
...- Germline BRCA1 or BRCA2 mutation that is considered deleterious or suspected deleterious (include those mutations or translocations termed "deleterious" or "suspected deleterious" according to lab reporting)....
Trial ID:
Source:
Title:
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Excerpt:
...For patients enrolling in the sporadic serous epithelial ovarian cancer group, Group B, a negative family history (BRCAPRO score less than or equal to 20% or negative BRCA1/2 mutation test)....
Trial ID:
More C2 evidence
Source:
Title:
ANZ 1103 Study of Olaparib Clinical Effect in Patients with Breast Cancer or Ovarian Cancer
Excerpt:
...b) Male or female with histologically confirmed, metastatic breast cancer and documented BRCA1 or BRCA2 germline mutation, regardless of tumour steroid hormone receptor or HER-2 status OR...
Trial ID:
Source:
Title:
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
Excerpt:
...Assess the efficacy of olaparib in HER2-negative early Breast Cancer and HRD (BRCA 1/2 mutations and/or HRD positive). ...
Trial ID:
Source:
Title:
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Excerpt:
...- Documented germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)....
Trial ID:
Source:
Title:
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
Excerpt:
...Cohort 1: Documented germline or somatic mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)....
Trial ID:
Source:
Title:
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Excerpt:
...Histologically confirmed recurrent and metastatic TNBC patients without BRCA1/2 mutation and BRCA1 promoter methylation....
Trial ID:
Less C2 evidence
Source:
Title:
Optimizing the management of early stage TNBC
Published date:
10/09/2021
Excerpt:
More recently, for patients with BRCA-mutated cancers, the OlympiA trial showed benefit to a year of adjuvant olaparib
Trial ID:
Source:
Title:
184PD - Neoadjuvant olaparib monotherapy in primary triple negative breast cancer (ID 3933)
Published date:
09/28/2019
Excerpt:
Among five patients harboring pathogenic BRCA1/2 mutations (4 germline, 1 somatic) all responded to olaparib, and n = 3/5 obtained pathological complete response...Olaparib yielded a high response rate when administered to treatment-naïve, large TNBC...
Trial ID:
Source:
Title:
Abstract 2212: An antibody drug conjugate targeting activated matriptase, exhibits synergistic cytotoxicity with a PARP inhibitor, olaparib in triple negative breast cancer
Published date:
05/15/2020
Excerpt:
The MDA-MB-468 cell line with a mutation in BRCA 2, and expression of activated matriptase was the most sensitive cell line to both olaparib and the chimeric MMAE ADC, and the combination of them resulted in marked synergistic cell kill.
DOI:
10.1158/1538-7445.AM2020-2212
